

**Harvard Medical School  
Curriculum Vitae**

**Date Prepared:** November 2, 2020

**Name:** Shayna Sarosiek

**Office Address:** Dana-Farber Cancer Institute  
450 Brookline Avenue, Mayer 223  
Boston, MA 02215

**Work Phone:** 617-632-6140

**Work Email:** Shayna\_Sarosiek@dfci.harvard.edu

**Work Fax:** 617-632-5175

**Place of Birth:** Alpena, Michigan

**Education**

2002	BA	Spanish Literature; minor in Biology	Wake Forest, Winston-Salem, NC
2005	MS	Biomedicine	Barry University, Miami, FL
2009	MD	Medicine	University of Miami School of Medicine, Miami, FL

**Postdoctoral Training**

7/2009-6/2012	Intern and Resident	Internal Medicine	Boston University School of Medicine (BUSM), Boston, MA
7/2012-6/2013	Clinical Fellow	Medicine (Hematology & Oncology)	BUSM
7/2013-6/2015	Clinical Fellow	Hematology and Oncology	BUSM
7/2015-6/2016	Chief Fellow	Hematology and Oncology	BUSM

### **Faculty Academic Appointments**

7/2012-6/2013	Instructor	Medicine (Hematology & Oncology)	BUSM
7/2016-9/2020	Assistant Professor	Medicine (Hematology Oncology)	BUSM

### **Appointments at Hospitals/Affiliated Institutions**

7/2012-6/2013	Physician	Medicine (Hematology/Medical Oncology)	Boston Medical Center (BMC), Boston, MA
7/2016-9/2020	Physician	Medicine (Hematology/Medical Oncology)	BMC
10/2020-	Physician	Medical Oncology	Dana-Farber Cancer Institute (DFCI), Boston, MA
10/2020-	Associate Physician	Medicine (Medical Oncology)	Brigham and Women's Hospital (BWH), Boston, MA

### **Committee Service**

#### **Local**

2016-2020	Admissions Committee, Hematology and Medical Oncology Fellowship	BMC
-----------	--	-----

#### **National**

2019-	Medical Knowledge Self-Assessment Program (MKSAP) – Hematology Committee	American College of Physicians
-------	--	--------------------------------

### **Professional Societies**

2009-2018	Massachusetts Medical Society (MMS)
2013-	American Society of Hematology (ASH)
2018-	International Society of Amyloidosis (ISA)

## **Grant Review Activities**

2018-2020	Clinical and Translational Science Institute (CTSI) Integrated Pilot Grant	BUSM
-----------	---	------

## **Editorial Activities**

### ***Ad hoc Reviewer***

*Amyloid Journal*  
*Biology of Blood and Marrow Transplantation*  
*Blood Advances*  
*BMJ*  
*JAMA Internal Medicine*  
*Journal of Clinical Oncology*  
*Journal of Hospital Medicine*  
*Journal of Pediatric Hematology and Oncology*  
*Leukemia and Lymphoma*  
*Therapeutic Advances in Hematology*

## **Honors and Prizes**

2015	T32 Training Grant	National Institutes of Health (NIH)
2018	Junior Researcher Travel Grant	Amyloidosis Foundation
2019	Junior Faculty Mentoring Award	BUSM

## **Report of Funded and Unfunded Projects**

### **Funding Information**

#### **Past**

2017-2018	Apoptotic Dependencies in AL Amyloidosis NIH Pilot Grant UL1 TR001430 PI The goal of this study was to examine apoptotic dependencies on clonal plasma cells from patients with AL amyloidosis.
2017-2020	A Phase II Single-Center, Open Label, Safety and Efficacy Study of Propylene Glycol-Free Melphalan (Evomela) in AL Amyloidosis Patient Undergoing Autologous Stem Cell Transplantation Acrotech (Investigator-initiated) PI

The goal of this study is to assess safety and efficacy of propylene glycol-free melphalan in patients with AL amyloidosis undergoing autologous stem cell transplantation. My participation in this project ended upon joining DFCI.

2020-2020 Etoposide in COVID-19  
 NIH UL1 TR001430  
 Co-investigator (PI: J. Mark Sloan)  
 The goal of this study is to assess the safety of using etoposide for treatment of patients with COVID-19 who harbor features similar to HLH. My participation in this project ended upon joining DFCI.

### **Unfunded Current Projects**

2016- Assessment of Minimal Residual Disease in AL Amyloidosis: Extension Study (PI)  
 The goal of this study is to assess the utility of MRD in the assessment of disease burden in patients with AL amyloidosis.

2019- Kappa and Lambda AL Amyloidosis (PI)  
 The goal of this study is to assess the difference in patient characteristics and outcomes in patients with AL amyloidosis based on their underlying plasma cell clone (kappa v. lambda).

2020- Inflammatory Markers in AL Amyloidosis (PI)  
 The goal of this study is to assess the significance of inflammatory markers in predicting outcomes in patients with AL amyloidosis.

2020- Cerebrovascular Events in Patients Being Treated with CyBorD (PI)  
 The goal of this study is to assess the characteristics of patients with AL amyloidosis who are diagnosed with a stroke during treatment with CyBorD based on cases available for review in the BU Amyloidosis Database

### **Report of Local Teaching and Training**

#### **Teaching of Students in Courses**

##### **BUSM**

2013-2020	Disease and Therapy: Hematology Module (MED MS 220) First year medical students	BUSM 3-4 hours per year
2015-2016	Introduction to Clinical Medicine Course (MED MS 214) Second year medical students	BUSM 3-4 hours per year
2016-2020	Organ System Disease (GMS MM 707), Molecular and Translational Medicine Program Graduate students	Graduate Medical Sciences, BUSM 2 hours per year

2017-2020	Medical Challenges for the Dental Patient – Hematology Dental students	Goldman School of Dental Medicine, BUSM 2 hours per year
2017-2020	General Medicine and Dental Correlations – Hematology Dental students	Goldman School of Medicine – BUSM  2 hours per year

### **Other Harvard University Courses**

2020-	Human Pathophysiology - Hematology (EH208/BPH210)	Harvard T.H. Chan School of Public Health (HSPH), Boston, MA
-------	--	---

### **Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)**

2012-2020	Core Topics in Hematology/Oncology Internal Medicine (IM) residents	BMC 3-5 1-hour lectures per year
2016-2020	Hematology Introduction, Fellowship Bootcamp: Topics - Peripheral smear interpretation; Hematologic emergencies; Acute Leukemia Medical Oncology fellows	Hematology/Medical Oncology, BMC  3 1-hour lectures per year
2016-2020	Hematology/Oncology Fellowship Teaching Conferences – Topics: Waldenström Macroglobulinemia; Autologous and Allogeneic Stem Cell Transplantation; AL Amyloidosis; Chronic lymphocytic leukemia; Plasma cell disorders; Thrombocytopenia; Myeloproliferative disorders; Myelodysplastic syndrome; Aplastic Anemia; Heparin-Induced Thrombocytopenia and Thrombosis Medical Oncology fellows	Hematology/Medical Oncology, BMC  10 1-hr lectures per year

### **Clinical Supervisory and Training Responsibilities**

2016-2020	Ambulatory Clinic Preceptor Medical students, IM residents, Medical Oncology fellows	BMC 3 half-day sessions per week
2020-	Inpatient Attending, Medical Oncology Medical students, residents, fellows	BWH 6-7 hours per day, 7 days per week, 8 weeks per year

## **Laboratory and Other Research Supervisory and Training Responsibilities**

2016-2020	Research supervision Students, residents, fellows	BMC 5 hours per week
-----------	--	-------------------------

## **Mentored Trainees and Faculty**

2016-2018	<p>Pooja Phull, MD / Clinical Fellow, Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA <i>Career stage:</i> Amyloidosis fellow // <i>Mentoring role:</i> Mentor <i>Accomplishments:</i> Worked on research focused on determining the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in patients with transthyretin (TTR) amyloidosis; first-author manuscripts in <i>Amyloid</i> and <i>Bone Marrow Transplantation</i>; contributing author to an additional article published in <i>Bone Marrow Transplantation</i>. Oral presentation at the 2018 International Symposium on Amyloidosis in Japan; conducted a review of BMC's experience with autologous stem cell transplantation in patients with AL amyloidosis and a cardiac defibrillator. Manuscript published.</p>	
2016-2019	<p>Paul White, MD / Oncologist, Kootenai Health, Couer d'Alene, ID <i>Career stage:</i> Hematology/ Oncology fellow // <i>Mentoring role:</i> Mentor <i>Accomplishments:</i> Conducted a retrospective review of the use of bone modifying agents and resulting complications in cancer patients at Boston Medical Center. Manuscript accepted for publication – JNCCN April 2020.</p>	
2017-2018	<p>Anita Pudusseri, DO, Hematologist/Oncologist, Hematology/Oncology Associates (HOA) Centers for Cancer Care and Blood Disorders, Syracuse, NY <i>Career stage:</i> Fellow // <i>Mentoring role:</i> Mentor <i>Accomplishments:</i> Conducted research that investigated the prognostic significance of d-dimer in AL amyloidosis; poster presented at the 2018 International Symposium on Amyloidosis. Manuscript published in the <i>American Journal of Hematology</i>.</p>	
2017-2019	<p>Diana Cirstea, MD, Physician, Medical Oncology, DFCI, Instructor, Medicine, HMS <i>Career stage:</i> Fellow // <i>Mentoring role:</i> Mentor <i>Accomplishments:</i> Review of a single institution experience of the cytogenetic findings in minority patients with multiple myeloma; contributing author on a manuscript published in <i>Leukemia and Lymphoma</i>.</p>	
2018-2019	<p>Cara Pepler (Nee: Gandy), Associate Director, Clinical Quality, TG Therapeutics, Inc, Somersworth, NH <i>Career stage:</i> Masters student // <i>Mentoring role:</i> Mentor <i>Accomplishments:</i> Review of the outcomes of AL amyloidosis after stem cell transplantation with a focus on difference in outcomes between kappa and lambda plasma cell dyscrasia. Project completed as Capstone Project for Master's program and now an academic manuscript is being prepared for submission.</p>	
2018-2019	<p>Evan Catudal, MS, Project Coordinator, Pharmica Consulting, Los Angeles, CA <i>Career stage:</i> Masters student // <i>Mentoring role:</i> Mentor</p>	

*Accomplishments:* Review of cancer outcomes in patients with substance abuse disorder. Data collection complete and data analysis is ongoing.

2018-2020 Camille Edwards, MD, Hematologist/Oncologist, BMC, Assistant Professor of Medicine, BUSM

*Career stage:* Fellow, junior faculty // *Mentoring role:* Mentor

*Accomplishments:* Review of cancer outcomes in patients with substance abuse disorder. Data collection complete and data analysis is ongoing.

2018-2020 Asaf Maoz, MD, Hematology/Oncology Fellow, DFCI

*Career stage:* Resident; fellow // *Mentoring role:* Mentor

*Accomplishments:* Review of a single institution experience in the treatment of multiple myeloma in minority patients. Contributing author on publication in *Leukemia and Lymphoma*. Review of the incidence of ocular complications associated with bortezomib use. Contributing author on the manuscript published in *American Journal of Hematology*.

2018- Michael Dennis, MD, Hematology and Oncology Fellow, University of California, San Francisco, San Francisco, CA

*Career stage:* Resident // *Mentoring role:* Mentor

*Accomplishments:* Review of cancer outcomes in patients with substance use disorder. Data collection complete and data analysis is ongoing. Review in *Leukemia and Lymphoma* of a single institution experience in the treatment of multiple myeloma in minority patients. Review in the *American Journal of Hematology* of the incidence of ocular complications associated with bortezomib use; manuscript published. Retrospective review of the use of bone modifying agents and resulting complications in cancer patients at Boston Medical Center published in *JNCCN*.

2019- Rena Zheng, MD, Hematology/Oncology, BUSM

*Career stage:* Resident // *Mentoring role:* Mentor

*Accomplishments:* Evaluation of the prognostic significance of inflammatory markers in AL amyloidosis; data collection ongoing.

2020- Colin Pierce, MD, Internal Medicine Resident, BMC, BUSM

*Career stage:* Resident // *Mentoring role:* Mentor

*Accomplishments:* Review of the experience of patients with AL amyloidosis and CVA during treatment with CyBorD; data collection ongoing.

### **Local Invited Presentations**

*No presentations below were sponsored by outside entities.*

2012 IVC Filter Practices at Boston Medical Center / Grand Rounds  
Vascular Surgery and Vascular Medicine, BUSM/BMC

2012 Understanding IVC Filters and the Role of the Primary Care Physician / Grand Rounds  
Ambulatory Medicine, Department of Medicine, BUSM/BMC

- 2015 Morbidity and Mortality: Colonic Perforation as a Complication of Colon Cancer Treatment / Grand Rounds  
Section of Hematology/Oncology, Department of Medicine, BMC
- 2015 IVC Filter Use in Trauma Patients / Grand Rounds  
Section of Hematology and Medical Oncology, Department of Medicine, BMC
- 2016 Anemia in the Older Patients / Grand Rounds  
Section of Geriatrics, Department of Medicine, BMC
- 2020 Monoclonal Gammopathy of Undetermined Significance in ATTR Amyloidosis / Grand Rounds  
Section of Hematology/Oncology, Department of Medicine, BMC

## **Report of Regional, National and International Invited Teaching and Presentations**

### **Invited Presentations and Courses**

*No presentations below were sponsored by outside entities.*

#### **Regional Abstract Oral Presentations**

- 2010 Side Effects of Disease and Treatment in Secondary Raynaud Phenomenon / Invited speaker  
Society of General Internal Medicine Regional Meeting, Providence, RI

#### **National**

- 2016 AL Amyloidosis: From Diagnosis to Treatment / Invited speaker  
Division of Hematology & Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC
- 2017 Unfolding the Mysteries of AL Amyloidosis / Invited speaker  
Division of Hematology, Albert Einstein College of Medicine, New York, NY
- 2017 AL Amyloidosis: An Under-Diagnosed Disorder / Invited speaker  
International Myeloma Society Educational Workshop, Washington, DC

#### **International Abstract Oral Presentations**

- 2018 Monoclonal Gammopathy in Patients with Systemic Transthyretin Amyloidosis  
International Symposium on Amyloidosis, Kumamoto, Japan
- 2020 Comparison of Measures of Complete Hematologic Response after High-dose Melphalan and Autologous Stem Cell Transplantation for AL Amyloidosis  
International Symposium on Amyloidosis, Tarragona, Spain



## **Report of Clinical Activities and Innovations**

### **Current Licensure and Certification**

2012-	Massachusetts Medical License
2012-	Diplomate, Internal Medicine, American Board of Internal Medicine (ABIM)
2015-	Certified, Basic Life Support
2016-	Diplomate, Hematology, ABIM
2016-	Diplomate, Medical Oncology, ABIM

### **Practice Activities**

2012-2013	Ambulatory Care	Internal Medicine, BU Amyloidosis Center	Five half-day sessions per week
2016-2020	Ambulatory Care	Hematology & Oncology, BUSM/BMC	Four half-day sessions per week
2016-2020	Inpatient Care	Hematology & Oncology, BUSM/BMC	Average 12 weeks per year
2020-	Inpatient Care	Medical Oncology, BWH	8 weeks per year
2020-	Ambulatory Care	Medical Oncology, DFCI	5 half-day sessions per week

### **Clinical Innovations**

IVC Filter Retrieval Improvement (2010-	This initiative, started due to my research/work as an internal medicine resident, has led to marked improvements in the rate of IVC filter retrieval at BMC. Through this initiative patients are now given educational material about the IVC filter that is placed and all patients with an IVC filter placed are now tracked in a database and scheduled for follow-up in the IVC filter clinic to discuss filter removal. Results of this research were published in <i>JAMA Internal Medicine</i> and <i>Journal of Vascular Surgery</i> as well as nationwide when it was cited in the first annual ASH “Choosing Wisely” guidelines.
---	--

## **Report of Education of Patients and Service to the Community**

### **Activities**

2017-2020	Amyloidosis Support Group / Clinician Participated in Amyloidosis Support Group meetings throughout the nation and gave presentations about amyloidosis.
-----------	---

## **Report of Scholarship**

**ORCID ID: 0000-0002-0075-6735**

†Corresponding author

\*\* Mentee

## Peer-reviewed publications in print or other media

### Research investigations

1. **Sarosiek S**†, Crowther M, Sloan JM. Indications, complications and management of IVC filters: the experience in 952 patients at an academic hospital with a Level I trauma center. *JAMA Intern Med.* 2013;173(7):513-17. PMID: 23552968
2. Kalish J, Sloan M, **Sarosiek S**, Marks H, Moreira C, Hamburg N, Vilvendhan R, Farber A. Tracking breeds success: Improved retrieval rates of inferior vena cava filters with minimal dedication of resources. *J Vasc Surg Venous Lymphat Disord.* 2014;2(1):117. PMID: 26993020
3. Inagaki E, Farber A, Eslami M, Siracuse J, Rybin D, **Sarosiek S**, Sloan JM, Kalish J. Improving the retrieval rate of inferior vena cava filters with a multidisciplinary team approach. *J Vasc Surg Venous Lymphat Disord.* 2016;4(3):276-82. PMID: 27318045; PMCID: PMC5531451
4. **Sarosiek S**†, Rybin D, Weinberg J, Burke P, Kasotakis G, Sloan JM. Association between inferior vena cava filter insertion in trauma patients and in-hospital and overall mortality. *JAMA Surg.* 2017;152(1):75-81. PMID: 27682367

Commentary in: Waltz P, Zuckerbraun BS. Inferior vena cava filters in trauma patients-for whom the benefit tolls? *JAMA Surg.* 2017;152(1):81. PMID: 27681537

Commentary in: Yang GP, Wren M. Enhancing local resources in low- and middle-income countries through education. *JAMA Surg.* 2017;152(1):73-4. PMID: 27706484

Commentary in: Fitzgerald MC, Mitra B. Inferior vena caval filter insertion in trauma patients. *JAMA Surg.* 2017;152(7):706. PMID: 28384674

**Sarosiek S**, Rybin D, Kasotakis G. Inferior vena cava filter insertion in trauma patients-reply. *JAMA Surg.* 2017;152(7):707. PMID: 28384679

5. Browning S, Quillen K, Sloan JM, Doros G, **Sarosiek S**, Sanchorawala V. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. *Blood.* 2017;130(11):1383-86. PMID: 28698204
6. Batalini F, Econimo L, Quillen K, Sloan JM, **Sarosiek S**, Brauneis D, Havasi A, Stern L, Dember L, Sanchorawala V. High-dose melphalan and stem cell transplantation in patients on dialysis due to AL amyloidosis and monoclonal immunoglobulin deposition disease. *Biol Blood Marrow Transplant.* 2018;24(1):127-32. PMID: 28865972
7. Phull P\*\*, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, **Sarosiek S**†. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). *Amyloid.* 2018;25(1):62-7. PMID: 29424556; PMCID: PMC6157907
8. Pudusseri A, Smith I, Sarnacki D, Brauneis D, Shelton A, Sanchorawala V, Sloan JM, **Sarosiek S**, Quillen K. Evaluation of a new continuous mononuclear cell collection procedure in a single

- transplant center cohort enriched for AL amyloidosis patients. *Transfus Apher Sci.* 2018; 57(3):411-15. PMID: 29731423
9. White PS, Phull P, Brauneis D, Sloan JM, Quillen K, **Sarosiak S**, Sanchorawala V. High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers. *Bone Marrow Transplant.* 2018;53(12):1593-95. PMID: 29884854
  10. **Sarosiak S**†, Quillen K, Sloan JM, Brauneis D, Sanchorawala V. Heparin-induced thrombocytopenia and thrombosis during high-dose melphalan and autologous stem cell transplantation. *Blood.* 2018;132(7):755-7. PMID: 29903887
  11. Nguyen VP, Landau H, Quillen K, Brauneis D, Shelton AC, Mendelson L, Rahman H, Sloan JM, **Sarosiak S**, Sanchorawala V. Modified high-dose melphalan and autologous stem cell transplantation for immunoglobulin light chain amyloidosis. *Biol Blood Marrow Transplant.* 2018;24(9):1823-7. PMID: 29933072
  12. Angel-Korman A, Stern L, **Sarosiak S**, Sloan JM, Doros G, Sanchorawala V, Havasi A. Long-term outcome of kidney transplantation in AL amyloidosis. *Kidney Int.* 2019;95(2):405-11. PMID: 30580886
  13. Gupta VK, Brauneis D, Shelton AC, Quillen K, **Sarosiak S**, Sloan JM, Sanchorawala V. Induction therapy with bortezomib and dexamethasone and conditioning with high-dose melphalan and bortezomib followed by autologous stem cell transplantation for AL amyloidosis: Long term follow-up analysis. *Biol Blood Marrow Transplant.* 2019;25(5)e169-e73. PMID: 30639823
  14. Dennis M\*\*, Maoz A, Hughes D, Sanchorawala V, Sloan JM, **Sarosiak S**†. Bortezomib Ocular Toxicities: Outcomes with Ketotifen. *Am J Hematol.* 2019;94(3):E80-E2. PMID: 30575098
  15. Phull P\*\*, Sanchorawala V, Brauneis D, Sloan JM, Siddiqi OK, Quillen K, **Sarosiak S**†. High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators. *Bone Marrow Transplant.* 2019;54(8):1304-9. PMID: 30664726
  16. **Sarosiak S**, Sanchorawala V. Treatment options for relapsed/refractory systemic light-chain (AL) amyloidosis: Current perspectives. *J Blood Med.* 2019;10:373-80. PMID: 31695543
  17. Pudusseri A\*\*, Sanchorawala V, Sloan JM, Bever KM, Doros G, Katraia S, **Sarosiak S**†. Prevalence and prognostic value of D-dimer elevation in patients with AL amyloidosis. *Am J Hematol.* 2019;94(10):1098-1103. PMID:31292986
  18. Gupta VK, White PS, Brauneis D, Shelton AC, Quillen K, Sanchorawala V, **Sarosiak S**, Sloan JM. Safety of autologous stem cell transplantation in patients with known HTLV-1/2 infection: A case series of 4 patients. *Am J Hematol.* 2019;94(12):E317-E19. PMID: 31489689
  19. Sanchorawala V, **Sarosiak S**, Schulman A, Mistark M, Migre ME, Cruz R, Sloan JM, Brauneis D, Shelton AC. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: Results of a Phase II study. *Blood.* 2020;135(18):1541-7. PMID: 31978210

20. Staron A, Burks EJ, Lee JC, **Sarosiak S**, Sloan JM, Sanchorawala V. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis. *Blood Adv.* 2020;4(5):880-4. PMID: 32130406; PMCID: PMC7065470
21. White PS\*\*, Dennis M, Jones EA, Weinberg JM, **Sarosiak S**†. Risk factors for development of hypocalcemia in patients with cancer treated with bone-modifying agents. *J Natl Compr Canc Netw.* 2020;18(4):420-7. PMID: 32259788
22. Angel-Korman A, Stern L, Angel Y, **Sarosiak S**, Menn-Josephy H, Francis J, Ghai S, Sloan JM, Sanchorawala V, Havasi A. The role of kidney transplantation in monoclonal Ig deposition disease. *Kidney Int Rep.* 2020;5(4):485-93. PMID: 32274452; PMCID: PMC7136323
23. Dennis M\*\*, Maoz A, Cirstea D, Patel A, Lerner A, **Sarosiak S**†. Treatment disparities in minority groups with multiple myeloma at a safety-net hospital. *Leuk Lymphoma.* 2020;1-4. PMID: 32460648
24. Dumas B, Yameen H, **Sarosiak S**, Sloan JM, Sanchorawala V. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. *Amyloid.* 2020; Jun 19;1-6. Online ahead of print. PMID: 32551974
25. Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q, Kataria Y, **Sarosiak S**, Lerner A, Sloan JM, Quillen K, Burks EJ. SARS-CoV-2 infection-associated hemophagocytic lymphohistiocytosis. *Am J Clin Pathol.* 2020;154(4):466-74. PMID: 32681166
26. Szalat R, **Sarosiak S**, Havasi A, Brauneis D, Sloan JM, Sanchorawala V. Organ responses after high-dose melphalan and stem cell transplantation in AL amyloidosis. *Leukemia.* 2020 Jul. Online ahead of print. PMID: 32737434
27. **Sarosiak S**, Zheng L, Sloan JM, Quillen K, Brauneis D, Sanchorawala V. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. *Blood Cancer J.* 2020;10(8):88. PMID: 32873776; PMCID: PMC7462849

### Other peer-reviewed publications

1. **Sarosiak S**, Seldin DC, Berk JL, Sanchorawala V. A solitary mediastinal mass due to localized AL amyloidosis: case report and review of literature. *Amyloid.* 2013;20(2):127-30. PMID: 23461593
2. **Sarosiak S**, Seldin DC, Connors LH, Spencer B, Murakami A, O'Hara C, Sanchorawala V. Vertebral compression fractures as the initial presentation of AL amyloidosis: case series and review of the literature. *Amyloid.* 2015;22(3):156-62. PMID: 26104853
3. **Sarosiak S**, Shah R, Munshi N. Review of siltuximab in the treatment of multicentric Castleman's disease. *Ther Adv Hematol.* 2016;7(6):360-6. PMID: 27904739; PMCID: PMC5089324

4. Nlandu Z, **Sarosiek S**, Zhao Q, Mercier G, Kuhnen A, Hartshorn K. Anal squamous cell cancer in a patient with Human Immunodeficiency Virus Type 2 Infection: Report of a case and review of the literature. *JJ Aids HIV*. 2016;2(1):014.
5. Tran A, **Sarosiek S**, Ko NY. Challenges in the use of immunotherapy in metastatic melanoma. *BMJ Case Rep*. 2016;2016:bcr2016216681. PMID: 27864299; PMCID: PMC5129100
6. Dittus C, **Sarosiek S**. A case of HIV-negative plasmablastic lymphoma of the bone marrow with a unique immunophenotype. *Clin Case Rep*. 2017;5(6):902-4. PMID: 28588836; PMCID: PMC5458007
7. Nwabudike SM, Edwards CV, Akinboro O, Quinn K, **Sarosiek S**, Ko N. Cyclin-dependent kinase 4/6 inhibitor (palbociclib) induced aplastic anemia in a patient with metastatic breast cancer. *Case Rep Hematol*. 2018;2018:9249506. PMID: 30647983; PMCID: PMC6311830
8. Nguyen VP, Brauneis D, Kaku M, Sloan JM, **Sarosiek S**, Quillen K, Shelton AC, Sanchorawala V. Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis. *Bone Marrow Transplant*. 2018;53(3):371-373. PMID: 29269794
9. Jhaveri T, **Sarosiek S**, Ruberg FL, Siddiqi O, Berk JL, Sanchorawala V. Once AL amyloidosis: not always AL amyloidosis. *Amyloid*. 2018;8:1-2. PMID: 29516761
10. Batalini F, Aleixo GF, Maoz A, **Sarosiek S**. Haemodialysis-associated thrombocytopenia: interactions among the immune system, membranes, and sterilization methods. *BMJ Case Rep*. 2019;12(9):e229594. PMID: 31488440; PMCID: PMC6731774 (available on 2021-09-04)
- 11.

#### **Non-peer reviewed scientific or medical publications/materials in print or other media**

##### **Reviews, chapters, monographs and editorials**

1. Dittus C, **Sarosiek S**, Ansell J. Prevention of Venous Thromboembolism. In: Abutalib SA, Connors JM, Ragini MV, eds. *Nonmalignant Hematology. Expert Clinical Review: Questions and Answers*. Springer International Publishing Switzerland, pp. 429-44.
2. **Sarosiek S**, Castillo JJ. Novel Therapeutics in the Management of Waldenstrom Macroglobulinemia. In: Dittus J ed. *Novel Therapeutics for Rare Lymphomas*. Springer Nature Switzerland, pp. 15-26.

##### **Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings**

1. **Sarosiek S**, Jacob A, Fulcinti Mariateresa, Munshi N, Sanchorawala V, Varga C. Detection of circulating clonal plasma cells using next generation sequencing in patients with AL amyloidosis and low plasma cell burden: a novel discovery. *International Symposium on Amyloidosis 2018; Kumamoto, Japan*
2. Fraser C, Sanchorawala V, Sarosiek K and **Sarosiek S**. Clonal plasma cells in AL amyloidosis

are dependent on anti-apoptotic BCL-2 family proteins. American Society of Hematology 2018 National Meeting; San Diego CA

3. Jhaveri R, Sanchorawala V, Sloan JM, Lerner A, **Sarosiek S**, Shah B. Successful transition from bortezomib subcutaneous to generic intravenous bortezomib: Cost savings initiative with global economic impact. American Society of Hematology 2019 National Meeting; Orlando FL
4. **Sarosiek S**, Sloan JM, Quillen K, Brauneis D, Cruz R, Schulman A, Fennessey S, Shelton A, Sanchorawala V. Safety and efficacy of propylene glycol-free melphalan (Evomela) in patients with AL amyloidosis undergoing autologous stem cell transplantation: Preliminary results of a phase II study. American Society of Hematology 2019 National Meeting; Orlando FL
5. **Sarosiek S**, Sanchorawala V, Fulcinti M, Jacob AP, Munshi NC, Varga C. The use of next generation gene sequencing to measure minimal residual disease in patients with AL amyloidosis and low plasma cell burden: A feasibility study. American Society of Hematology 2019 National Meeting; Orlando FL
6. Acevedo J, Doros G, Szalat R, Sloan JM, **Sarosiek S**, Sanchorawala V. Clinical characteristics, treatment regimens and survival in elderly patients with AL amyloidosis in a tertiary referral center. American Society of Hematology 2019 National Meeting; Orlando FL
7. Parker T, Chansky K, Sanchorawala V, Landau H, Campagnaro E, Kapoor P, Neparidze N, Kagen P, **Sarosiek S**, Scott E, Hoering A, Orłowski R. A phase II study of isatuximab for patients with previously treated AL amyloidosis. International Society of Amyloidosis 2020; Tarragona Spain (virtual meeting)
8. **Sarosiek S**, Sloan JM, Quillen K, Brauneis D, Cruz R, Schulman A, Fennessey S, Shelton A, Sanchorawala V. A phase II study of propylene glycol-free melphalan in patients with AL amyloidosis undergoing autologous stem cell transplant: Preliminary results. International Society of Amyloidosis 2020; Tarragona Spain (virtual meeting)
9. Acevedo J, Doros G, Szalat R, **Sarosiek S**, Sloan JM, Sanchorawala V. Clinical characteristics, treatment regimens and survival in elderly patients with AL amyloidosis in tertiary referral center. International Society of Amyloidosis 2020; Tarragona Spain (virtual meeting)
10. **Sarosiek S**, Sanchorawala V, Fulcinti M, Jacob A, Munshi N, Varga C. Next generation gene sequencing to measure minimal residual disease in patients with AL amyloidosis and low plasma cell burden: A feasibility study. International Society of Amyloidosis 2020; Tarragona Spain (virtual meeting)

## **Narrative Report**

I am a Physician in Medical Oncology at DFCI and am applying for appointments of Associate Physician in Medical Oncology at BWH and Member of the Faculty of Medicine (holding appointment) at HMS, pending approval as Assistant Professor of Medicine. My Area of Excellence is Clinical Expertise and Innovation.

I was previously an Assistant Professor of Internal Medicine in the Section of Hematology & Medical Oncology at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC). My areas of excellence include the use of IVC filters, as well as plasma cell dyscrasias such as AL amyloidosis, concurrent MGUS and TTR amyloidosis, and multiple myeloma. I have received invitations to present my work and expertise on AL amyloidosis at various regional and national venues and have presented my research as oral abstracts at international meetings as well. My clinical activities at DFCI include attending on the inpatient Medical Oncology service at BWH 8 weeks per year and seeing patients in the ambulatory clinic in the Bing Center for Waldenström's Macroglobulinemia during 5 half-day sessions per week.

I have also dedicated my time to clinical research activities. As a young investigator in residency I initially published a manuscript in *JAMA Internal Medicine*, demonstrating the lack of retrieval of IVC filters at Boston Medical Center. This manuscript led to an evaluation of the practice of IVC filter placement at my institution, as well as nationwide, when it was cited in the first annual ASH "Choosing Wisely" guidelines. This project was then expanded and led to multiple other publications demonstrating the improvement in IVC filter retrieval rates at Boston Medical Center and the lack of an overall survival difference in patients with or without IVC filters placed upon treatment at our trauma center. After completing this research and beginning a fellowship at the Boston University Amyloidosis Center, I have now spent the majority of my research dedicated to amyloidosis and other plasma cell dyscrasias with contributions to many manuscripts describing outcomes in patients with not only AL amyloidosis, but also with multiple myeloma, and ATTR amyloidosis co-existing with monoclonal gammopathy of undetermined significance. My research in plasma cell dyscrasias will continue in my new position in which I will be involved in research, as well as clinical care, at the Bing Center for Waldenström's Macroglobulinemia.

During the years I have been a faculty member at BUSM/BMC, I have spent many hours contributing to the education of medical students, dental students, residents, and fellows through precepting in the ambulatory setting, teaching on inpatient services, and formal lectures as part of the structured educations for these trainees. My proposed teaching activities will include attending on the inpatient Medical Oncology service at BWH teaching students, residents, and fellows. I will also supervise and mentor trainees in my clinical research activities.